345 related articles for article (PubMed ID: 12218228)
1. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
3. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
4. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
[TBL] [Abstract][Full Text] [Related]
5. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
Miller AK; Dusing R; Meggison A; Aires D
J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
[TBL] [Abstract][Full Text] [Related]
6. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study.
Rosen T; Harting M; Gibson M
Dermatol Surg; 2007 Apr; 33(4):427-31; discussion 431-2. PubMed ID: 17430376
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
[TBL] [Abstract][Full Text] [Related]
10. [Topical treatment of melanoma skin metastases with imiquimod].
Sigüenza M; Pizarro A; Mayor M; Vidaurrázaga C; Miralles L; González-Beato M; Casado M
Actas Dermosifiliogr; 2005 Mar; 96(2):111-5. PubMed ID: 16476347
[TBL] [Abstract][Full Text] [Related]
11. [Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil].
Florin V; Vercambre-Darras S; Piette F; Mortier L
Ann Dermatol Venereol; 2008; 135(8-9):603-4. PubMed ID: 18789300
[No Abstract] [Full Text] [Related]
12. [In-transit metastasis in melanoma: Efficacy of topical imiquimod combined with carbon dioxide laser or with electrocautery].
Elfatoiki FZ; Longvert C; Clerici T; Bourgault-Villada I; Roudier-Pujol C; Vasseur E; Saiag P
Ann Dermatol Venereol; 2014 Feb; 141(2):106-10. PubMed ID: 24507204
[TBL] [Abstract][Full Text] [Related]
13. Treatment of in-transit melanoma with intralesional bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: a report of 3 cases.
Kibbi N; Ariyan S; Faries M; Choi JN
J Immunother; 2015; 38(9):371-5. PubMed ID: 26448581
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of Bowen's disease of the penis with imiquimod 5% cream].
de Diego Rodríguez E; Villanueva Peña A; Hernández Castrillo A; Gómez Ortega JM
Actas Urol Esp; 2005 Sep; 29(8):797-800. PubMed ID: 16304915
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.
Nouri K; O'Connell C; Rivas MP
J Drugs Dermatol; 2003 Dec; 2(6):669-73. PubMed ID: 14711149
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
Ray CM; Kluk M; Grin CM; Grant-Kels JM
Int J Dermatol; 2005 May; 44(5):428-34. PubMed ID: 15869545
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
Muñoz CM; Sánchez JL; Martín-García RF
Dermatol Surg; 2004 Dec; 30(12 Pt 2):1543-5. PubMed ID: 15606836
[TBL] [Abstract][Full Text] [Related]
18. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy.
Smith KJ; Germain M; Skelton H
Dermatol Surg; 2001 Feb; 27(2):143-6. PubMed ID: 11207687
[TBL] [Abstract][Full Text] [Related]
19. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
20. Innovative uses of imiquimod.
Vender RB; Goldberg O
J Drugs Dermatol; 2005; 4(1):58-63. PubMed ID: 15696986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
